Back to Journals » Drug Design, Development and Therapy » Volume 8

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Authors Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E

Received 4 June 2013

Accepted for publication 20 September 2013

Published 7 February 2014 Volume 2014:8 Pages 197—207

DOI https://doi.org/10.2147/DDDT.S49409

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Cristoforo Incorvaia,1 Marina Mauro,2 Marina Russello,2 Chiara Formigoni,3 Gian Galeazzo Riario-Sforza,1 Erminia Ridolo4

1Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, Milan, Italy; 2Allergy Unit, 3Scientific Library, Sant'Anna Hospital, Como, Italy; 4Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

Abstract: A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is effective also in nonallergic asthma. Effects on the complex signaling mechanisms leading to activation of effector cells and to mediator release may account for this outcome. Indeed, omalizumab has been reported to be effective in a number of IgE-mediated and non-IgE-mediated disorders. Concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis. In addition, omalizumab has been demonstrated to be able to prevent systemic reactions to allergen immunotherapy, thus enabling completion of treatment in patients who otherwise would have to stop it. Concerning non-IgE-mediated disorders, omalizumab has been reported to be effective in nasal polyposis, autoimmune urticaria, chronic idiopathic urticaria, physical urticaria, idiopathic angioedema, and mastocytosis. Current indications for treatment with omalizumab are confined to severe allergic asthma. Consequently, any other prescription can only be off-label. However, it is reasonable to expect that the use of omalizumab will be approved for particularly important indications, such as anaphylaxis, in the near future.

Keywords: hypersensitivity, immunoglobulin E, anti-IgE, omalizumab, asthma, atopic dermatitis, anaphylaxis, urticaria, mastocytosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Striving for optimal bronchodilation: focus on olodaterol

Incorvaia C, Montagni M, Makri E, Riario-Sforza GG, Ridolo E

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:439-444

Published Date: 1 March 2016

New combinations in the treatment of COPD: rationale for aclidinium–formoterol

Incorvaia C, Montagni M, Makri E, Ridolo E

Therapeutics and Clinical Risk Management 2016, 12:209-215

Published Date: 15 February 2016

Shrinking the room for invasive ventilation in hypercapnic respiratory failure

Scarpazza P, Incorvaia C, Melacini C, Cattaneo R, Bonacina C, Riario-Sforza GG, Casali W

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:135-137

Published Date: 15 March 2013

Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy

Frati F, Incorvaia C, David M, Scurati S, Seta S, Padua G, Cattaneo E, Cavaliere C, Di Rienzo A, Dell'Albani I, Puccinelli P

Drug Design, Development and Therapy 2012, 6:117-123

Published Date: 18 May 2012

Seroprevalence of IgG anti-Toxocara species antibodies in a population of patients with suspected allergy

Qualizza R, Incorvaia C, Grande R, Makri E, Allegra L

International Journal of General Medicine 2011, 4:783-787

Published Date: 22 November 2011

Long-term survival in elderly patients with a do-not-intubate order treated with noninvasive mechanical ventilation

Scarpazza P, Incorvaia C, Amboni P, di Franco G, Raschi S, Usai P, Bernareggi M, Bonacina C, Melacini C, Cattaneo R, Bencini S, Pravettoni C, Riario-Sforza GG, Passalacqua G, Casali W

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:253-257

Published Date: 26 April 2011

The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children

Cristoforo Incorvaia, Simonetta Masieri, Silvia Scurati, et al

Journal of Asthma and Allergy 2011, 4:13-17

Published Date: 20 February 2011

Development of a sublingual allergy vaccine for grass pollinosis

Franco Frati, Silvia Scurati, Paola Puccinelli, et al

Drug Design, Development and Therapy 2010, 4:99-105

Published Date: 17 June 2010

Adherence issues related to sublingual immunotherapy as perceived by allergists

Silvia Scurati, Franco Frati, Gianni Passalacqua, et al

Patient Preference and Adherence 2010, 4:141-145

Published Date: 15 June 2010

Effects of pulmonary rehabilitation on exercise capacity in patients with COPD: A number needed to treat study

Gian Galeazzo Riario-Sforza, Cristoforo Incorvaia, Fulvia Paterniti, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:315-319

Published Date: 21 August 2009

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010